Abstract
Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is a significant cause of morbidity, quality-of-life impairment and health-care costs. Although many patients can be treated satisfactorily with topical medications and phototherapy, a smaller subset requires more aggressive systemic therapies. Multiple studies have shown promise for the use of mycophenolate mofetil (MMF) to treat refractory AD. This report summarizes the evidence for use of MMF in the treatment of recalcitrant AD for both children and adults. Familiarity with these studies on the benefits and risks of MMF will enable the clinician and patient to select the most appropriate therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 715-718 |
| Number of pages | 4 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 15 |
| Issue number | 6 |
| State | Published - Jun 2016 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Mycophenolate mofetil in severe atopic dermatitis: A review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver